[
  {
    "ts": null,
    "headline": "Tempus Shares Jump After Strong Preliminary 2025 Results",
    "summary": "Investors Eye 2026 Guidance as Tempus AI Tops $1.1B in Contract Value",
    "url": "https://finnhub.io/api/news?id=686979a1fb16905d5efaf87fbfd2069526ea76d5517eb4566138dbd0b9d79802",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768242932,
      "headline": "Tempus Shares Jump After Strong Preliminary 2025 Results",
      "id": 138078087,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investors Eye 2026 Guidance as Tempus AI Tops $1.1B in Contract Value",
      "url": "https://finnhub.io/api/news?id=686979a1fb16905d5efaf87fbfd2069526ea76d5517eb4566138dbd0b9d79802"
    }
  },
  {
    "ts": null,
    "headline": "What $6,500 a Month Really Looks Like in Retirement at 67",
    "summary": "Retiring at 67 with $6,500 in monthly income places you solidly in middle-class territory, but the financial reality behind that figure is more nuanced than it appears. With average Social Security benefits at $2,017 per month in 2026, a retiree targeting $6,500 needs to generate roughly $4,483 monthly—or $53,796 annually—from personal savings and investments. The ... What $6,500 a Month Really Looks Like in Retirement at 67",
    "url": "https://finnhub.io/api/news?id=6893e956b6faae41cdb1adaa3ed4f00fff9f2f71cae9fb0f95d173a221eb60ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768240904,
      "headline": "What $6,500 a Month Really Looks Like in Retirement at 67",
      "id": 138078048,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Retiring at 67 with $6,500 in monthly income places you solidly in middle-class territory, but the financial reality behind that figure is more nuanced than it appears. With average Social Security benefits at $2,017 per month in 2026, a retiree targeting $6,500 needs to generate roughly $4,483 monthly—or $53,796 annually—from personal savings and investments. The ... What $6,500 a Month Really Looks Like in Retirement at 67",
      "url": "https://finnhub.io/api/news?id=6893e956b6faae41cdb1adaa3ed4f00fff9f2f71cae9fb0f95d173a221eb60ef"
    }
  },
  {
    "ts": null,
    "headline": "‘Biotech Super Bowl’ Lands With a Thud. Stocks Slide on Lack of Deal News.",
    "summary": "Monday is the first day of  J.P. Morgan’s  annual healthcare investor conference, which draws thousands of investors, analysts, and executives to San Francisco each year.  There is ample precedent: Last year,  Johnson & Johnson  announced a $14.6 billion deal to acquire Intra-Cellular Therapeutics on the first day of the gathering.  The Wall Street Journal reported last week that Merck was in talks to buy the biotech Revolution Medicines for roughly $30 billion, but as of late morning, no such agreement had been announced.",
    "url": "https://finnhub.io/api/news?id=a8e42fa0176125b6d61a239d1fc7e9d3ac654534ef8fe6ce6ee1a22fdfcc0ed8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768235880,
      "headline": "‘Biotech Super Bowl’ Lands With a Thud. Stocks Slide on Lack of Deal News.",
      "id": 138076408,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Monday is the first day of  J.P. Morgan’s  annual healthcare investor conference, which draws thousands of investors, analysts, and executives to San Francisco each year.  There is ample precedent: Last year,  Johnson & Johnson  announced a $14.6 billion deal to acquire Intra-Cellular Therapeutics on the first day of the gathering.  The Wall Street Journal reported last week that Merck was in talks to buy the biotech Revolution Medicines for roughly $30 billion, but as of late morning, no such agreement had been announced.",
      "url": "https://finnhub.io/api/news?id=a8e42fa0176125b6d61a239d1fc7e9d3ac654534ef8fe6ce6ee1a22fdfcc0ed8"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript",
    "summary": "Bristol-Myers Squibb Company (BMY) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 10:30 AM ESTCompany ParticipantsChristopher Boerner - CEO...",
    "url": "https://finnhub.io/api/news?id=c048d400ccc0ba302b5226bc34d7334cd149200e52e349ce914af00b03f83c66",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768232759,
      "headline": "Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript",
      "id": 138078586,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb Company (BMY) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 10:30 AM ESTCompany ParticipantsChristopher Boerner - CEO...",
      "url": "https://finnhub.io/api/news?id=c048d400ccc0ba302b5226bc34d7334cd149200e52e349ce914af00b03f83c66"
    }
  },
  {
    "ts": null,
    "headline": "Scotiabank Raises Bristol-Myers (BMY) PT to $60 Citing Catalyst-Rich 2026 Growth",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap stocks to buy for the next 3 years. On January 9, Scotiabank analyst Louise Chen raised the firm’s price target on Bristol-Myers to $60 from $53, while maintaining a Sector Perform rating on the shares. With the stock trading at an inexpensive valuation and several key […]",
    "url": "https://finnhub.io/api/news?id=4d2767b0f8c5def71088d475ff2a8239c971d1dcb869260006c6afa389476248",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768230722,
      "headline": "Scotiabank Raises Bristol-Myers (BMY) PT to $60 Citing Catalyst-Rich 2026 Growth",
      "id": 138075306,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap stocks to buy for the next 3 years. On January 9, Scotiabank analyst Louise Chen raised the firm’s price target on Bristol-Myers to $60 from $53, while maintaining a Sector Perform rating on the shares. With the stock trading at an inexpensive valuation and several key […]",
      "url": "https://finnhub.io/api/news?id=4d2767b0f8c5def71088d475ff2a8239c971d1dcb869260006c6afa389476248"
    }
  },
  {
    "ts": null,
    "headline": "3 Top Dividend Stocks to Maximize Your Retirement Income",
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "url": "https://finnhub.io/api/news?id=d44cbcbba852cd0762ac5f116eb17a5d12a6088a644f583eaea9f04e4aac622f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768227002,
      "headline": "3 Top Dividend Stocks to Maximize Your Retirement Income",
      "id": 138075307,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
      "url": "https://finnhub.io/api/news?id=d44cbcbba852cd0762ac5f116eb17a5d12a6088a644f583eaea9f04e4aac622f"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)",
    "summary": "PRINCETON, N.J., January 12, 2026--BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM",
    "url": "https://finnhub.io/api/news?id=dd9030ce5ad66def181b5cdac70ea7df5810dcae0cf82ed7cbb8b0a9d87cd8d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768219140,
      "headline": "Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)",
      "id": 138071516,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., January 12, 2026--BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM",
      "url": "https://finnhub.io/api/news?id=dd9030ce5ad66def181b5cdac70ea7df5810dcae0cf82ed7cbb8b0a9d87cd8d9"
    }
  }
]